TME Pharma N.V. Stock price




Biotechnology & Medical Research

Market Closed - Euronext Paris 11:20:05 2023-12-05 EST Intraday chart for TME Pharma N.V. 5-day change 1st Jan Change
0.25 EUR -3.85% 0.00% -79.44%


Sales 2023 * 40K 43.17K 58.6K Sales 2024 * 5.04M 5.44M 7.38M Capitalization 1.33M 1.43M 1.94M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 *
Net cash position 2023 * 570K 615K 835K Net cash position 2024 * 1.57M 1.69M 2.3M EV / Sales 2024 *
P/E ratio 2023 *
P/E ratio 2024 *
Employees 13
Yield 2023 *
Yield 2024 *
Free-Float 32.38%
More Fundamentals * Assessed data
Dynamic Chart
TME PHARMA : Invest Securities updates its target CF
TME Pharma: shares fall after capital increase CF
TME Pharma N.V. announced that it expects to receive ?2.7 million in funding CI
TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
TME Pharma N.V. Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer CI
TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting CI
Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer CI
TME Pharma N.V. Provides Positive Data Update on Best Response to Therapy with First Complete Response in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near- Complete Response CI
TME Pharma N.V. Announces Positive 15-Month Survival Data from Gloria Expansion Arm Evaluating NOX-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma CI
Appetite for Risk Surges
TME Pharma N.V. Receives Investigational New Drug Approval for NOX-A12 From the US FDA CI
TME Pharma N.V. Provides Positive Clinical Update and 14-Month Survival Data from Gloria Expansion Arm Evaluating Nox-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma CI
TME Pharma N.V. Auditor Raises 'Going Concern' Doubt CI
TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TME Pharma N.V. Announces a Clinical Update on Survival of Newly Diagnosed Glioblastoma Patients in the GLORIA Expansion Arm Evaluating NOX-A12, TME Pharma’s CXCL12 Inhibitor CI
More news
1 day-3.85%
Current month-7.41%
1 month-38.57%
3 months-85.62%
6 months-81.99%
Current year-79.44%
More quotes
1 week
Extreme 0.242
1 month
Extreme 0.24
Current year
Extreme 0.24
1 year
Extreme 0.24
3 years
Extreme 0.24
5 years
Extreme 0.24
10 years
Extreme 0.24
2 200.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 2010
Director of Finance/CFO - 1999
Investor Relations Contact - 2017
Members of the board TitleAgeSince
Director/Board Member 52 2020
Chairman 75 2016
Director/Board Member 57 2021
More insiders
Date Price Change Volume
23-12-05 0.25 -3.85% 65,434
23-12-04 0.26 +4.42% 48,355
23-12-01 0.249 -7.78% 384,489
23-11-30 0.27 +4.25% 121,956
23-11-29 0.259 +3.60% 477,613

Real-time Euronext Paris, December 05, 2023 at 11:20 am

More quotes
TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
More about the company
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock TME Pharma N.V. - Euronext Paris
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits